News | March 15, 2012

Interventional Cardiology Device Markets to Grow in Pakistan, Saudi Arabia, South Africa, Turkey

Large International Competitors Best Positioned to Benefit from Developing Regulations in These Countries, According to Millennium Research Group

March 15, 2012 — According to Millennium Research Group (MRG) the interventional cardiology (IC) market in Pakistan, Saudi Arabia, South Africa and Turkey will reach a value of more than $460 million by 2016.

The IC markets of Turkey and Saudi Arabia are growing rapidly as a result of increasingly aging populations, expanding economies, and a positive regulatory milieu. Pakistan and South Africa both suffer from regulatory uncertainty, poor reimbursement and healthcare inaccessibility in rural areas, and will grow more slowly. Over the next few years, developing regulatory processes in these countries will clarify the competitive landscape and favor large international competitors.

Historically, all of these countries have used European Union CE marking or United States Food and Drug Administration (FDA) medical device approval in lieu of their own medical device regulation, but each is developing its own regulatory process, with adoption more advanced in Turkey and Saudi Arabia.

Until recently Pakistan had no established medical device regulatory system. Devices approved in their country of origin could be freely imported. A domestic regulatory scheme was proposed in 2011, but recent changes in administration have left the process in flux. Poor reimbursement in Pakistan means that most costs are out-of-pocket, leading to a strong demand for cheap or smuggled devices from illicit manufacturers.

“Low regulatory barriers to entry have made these national markets attractive to smaller competitors,” said MRG analyst Mirel Giugaru. “In Pakistan, particularly, all regulatory costs had already been paid in the country of origin, so it was relatively easy to realize additional revenues. But as regulations become more stringent, the marginal cost of complying can go up significantly, which favors larger companies, who are better able to absorb these expenses. It will also reduce competition from smuggled medical devices, and less-expensive devices from smaller, less-regulated manufacturers. As a result, there is a strong possibility that the dominant international companies, Medtronic, Boston Scientific and Abbott Vascular, will be increasing their share in all of these countries.”

Millennium Research Group’s "Middle Eastern and South African Markets for Interventional Cardiology 2012" report includes procedure, unit, average selling price and revenue information, along with market drivers and limiters and competitive landscape for coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, and IC accessory devices in Pakistan, Saudi Arabia, South Africa and Turkey.

For more information:

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init